Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
- Thursday, July 21, 2022, 7:04
- Finance
- Add a comment
SALT LAKE CITY, July 21, 2022 /PRNewswire/ — Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the European Commission has granted Recursion Orphan Drug Designation for REC-4881 for the potential…
About the Author
adminasapcorp has written 41555 stories on this site.